Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes
Open accessPublished version of a preprint
The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 1 diabetes mellitus (T1DM) is a rare, irreversible immune-related adverse event reported in patients receiving treatment with immune checkpoint inhibitors (ICI). However, clinical risk factors for ICI-induced T1DM (ICI-T1DM) and its impact on survival in patients remain unknown. RESEARCH DESIGN AND METHODS: We used Optum's Clinformatics Data Mart database for assessment of the incidence and characteristics of T1DM in a large de-identified cohort of patients treated with ICI between 2017 and 2020. We applied Fine-Gray and cause-specific hazard models to study associations between patient/treatment characteristics and ICI-T1DM and applied the Cox model with ICI-T1DM as a time-varying covariate to assess the impact of ICI-T1DM on survival. RESULTS: ICI-T1DM was observed in 261 of 30,337 (0.86%) patients. Dual use of antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) was associated with increasing risk of ICI-T1DM (hazard ratio [HR] 1.62; 95% CI 1.15-2.26) vs. anti-PD-L1 or anti-PD-1 alone. Younger age (HR 1.19 for every 5-year decrease; 95% CI 1.13-1.25) and preexisting non-T1DM diabetes (HR 4.48; 95% CI 3.45-5.83) were also associated with higher risk of ICI-T1DM. Conversely, prior use of immunosuppressive medications (HR 0.57; 95% CI 0.34-0.95) was associated with lower incidence of ICI-T1DM, but part of its protective effect may be due to the increased mortality rate. Development of ICI-T1DM does not seem to significantly impact patient survival. CONCLUSIONS: The risk of ICI-T1DM is associated with the type of ICI therapy, patient age, and preexisting non-T1DM diabetes. These data may help guide risk assessment and screening practices for patients during ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fulminant onset of type 1 diabetes can occur, with DKA and low or undetectable levels of C-peptide as a marker of endogenous b -cell function (64 -66).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Moore, B. J., White, S., Washington, R., Coenen, N., & Elixhauser, A. (2017) · Medical Care · doi:10.1097/mlr.0000000000000735 · Cited by 827
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Imagawa, A., Hanafusa, T., Miyagawa, J.-I., & Matsuzawa, Y. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420501 · Cited by 652
Research works printed but not linked: 1
- 19. Nicolaides NC, Pavlaki AN, Alexandra MAM, et al. Glucocorticoid therapy and adrenal suppression. In Endoxtext. Feingold KR, Anawalt B, Boyce A, et al., Eds. South Dartmouth, MA, MDText.com, Inc., 2015
Cited by
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Cho, Y. K., & Jung, C. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0072 · Cited by 62
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
Ruiz-Esteves, K. N., SHANK, K. R., Deutsch, A. J., Gunturi, A., Chamorro-Pareja, N., Colling, C., Zubiri, L., Perlman, K., Ouyang, T., Villani, A., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3104 · Cited by 51
Type 1 diabetes: A new vision of the disease based on endotypes
Weston, C. S., Boehm, B. O., & Pozzilli, P. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3770 · Cited by 45
Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023
Pleus, S., Tytko, A., Landgraf, R., Heinemann, L., Werner, C., Müller‐Wieland, D., Ziegler, A., Müller, U. A., Freckmann, G., Kleinwechter, H. J., et al. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6643 · Cited by 45
Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus
Liao, D., Liu, C., Chen, S., Liu, F., Li, W., Shangguan, D., & Shi, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110414 · Cited by 37
Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence
Huang, Q., & Zhu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112724 · Cited by 34
Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
Kamitani, F., Nishioka, Y., Koizumi, M., Nakajima, H., Kurematsu, Y., Okada, S., Kubo, S., Myojin, T., Noda, T., Imamura, T., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14362 · Cited by 26
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2022
Landgraf, R., Heinemann, L., Schleicher, E. D., Gerdes, C., Petersmann, A., Müller‐Wieland, D., Müller, U. A., Freckmann, G., Thaler, M., Ziegler, A., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1789-5615 · Cited by 23
Muralidharan, C., Huang, F., Enriquez, J. R., Wang, J. E., Nelson, J. B., Nargis, T., May, S. C., Chakraborty, A., Figatner, K. T., Navitskaya, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176136 · Cited by 22
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus
Huang, M., Chen, W., Wang, M., Huang, Y., Liu, H., Ming, Y., Chen, Y., Tang, Z., & Jia, B. (2023) · BioDrugs · doi:10.1007/s40259-023-00594-6 · Cited by 20
Wei, H., Lai, Y., Lin, G., Lin, C.-W., Chang, Y.-C., Chang, J. W., Liou, M., & Chen, I.-W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01263-6 · Cited by 20
Shen, M., Chen, D., Zhao, R., Zheng, X., Gu, Y., Yang, T., & Shi, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1213225 · Cited by 16
Zatelli, M. C., Faggiano, A., Argentiero, A., Danesi, R., D’Oronzo, S., Fogli, S., Franchina, T., Giorgino, F., Marrano, N., Giuffrida, D., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102734 · Cited by 16
Delayed graft rejection in autoimmune islet transplantation via biomaterial immunotherapy
Coronel, M. M., Linderman, S. W., Martin, K. E., Hunckler, M. D., Medina, J. D., Barber, G. F., Riley, K., Yolcu, E. S., Shirwan, H., & García, A. J. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.07.023 · Cited by 16
Iwamoto, Y., Kimura, T., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Tatsumi, F., Shimoda, M., Nakanishi, S., Mune, T., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1079074 · Cited by 15
Lee, C. L., Riya, I. J., Piya, I. J., Muniz, T. P., Butler, M. O., & Saibil, S. D. (2025) · Cancers · doi:10.3390/cancers17071080 · Cited by 14
Life-threatening immune-related adverse events in the intensive care unit: a narrative review
Pichon, S., Zebian, G., Bureau, C., Levy, C., Lacombe, C., Desmedt, E., Wils, P., Merlen, E., Lionet, A., Terriou, L., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08155-x · Cited by 13
Deligiorgi, M. V., & Trafalis, D. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087630 · Cited by 13
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2023
Pleus, S., Tytko, A., Landgraf, R., Heinemann, L., Werner, C., Müller‐Wieland, D., Ziegler, A., Müller, U. A., Freckmann, G., Kleinwechter, H. J., et al. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2075-9943 · Cited by 13
Gómez, P. R. D. V., Piñar-Gutiérrez, A., Guerrero-Vázquez, R., Bellido, V., Morales, C., Sancho-Márquez, M. P., Espejo-García, P., Gros‐Herguido, N., López-Gallardo, G., Martínez‐Brocca, M. A., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4508633 · Cited by 12
Kotwal, A., Perlman, J. E., Goldner, W. S., Marr, A., & Mammen, J. S. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00023 · Cited by 11
Chen, Y., Wang, X., & Duan, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1679751 · Cited by 11
12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice
Nargis, T., Muralidharan, C., Enriquez, J. R., Wang, J. E., Kaylan, K. B., Chakraborty, A., Pratuangtham, S., Figatner, K. T., Nelson, J. B., May, S. C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.185299 · Cited by 11
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2024
Schwarz, T., Niederau, C. M., Pleus, S., Tytko, A., Landgraf, R., Werner, C., Müller‐Wieland, D., Müller, U. A., Freckmann, G., Schleicher, E. D., et al. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0252 · Cited by 10
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2022
Landgraf, R., Heinemann, L., Schleicher, E. D., Gerdes, C., Petersmann, A., Müller‐Wieland, D., Müller, U. A., Freckmann, G., Thaler, M., Ziegler, A., et al. (2023) · Die Diabetologie · doi:10.1007/s11428-022-00997-z · Cited by 10
Ginsenoside Rg1 Ameliorates Pancreatic Injuries via the AMPK/mTOR Pathway in vivo and in vitro
Chen, J., Zhu, G., Xiao, W., Huang, X., Wang, K., & Zong, Y. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s401642 · Cited by 10
Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors
Kamitani, F., Nishioka, Y., Nakajima, H., Kurematsu, Y., Okada, S., Myojin, T., Noda, T., Imamura, T., & Takahashi, Y. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf347 · Cited by 9
Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
Zhan, M., Long, Q., He, J., Huang, L., Wu, B., Xu, H., Li, M., & Xu, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499074 · Cited by 9
Ning, P., Liu, S., & Cao, H. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-023-04248-7 · Cited by 7
Diabetes and cancer: glucose control impact on survival and tumor outcomes
Ruggeri, R. M., Grossrubatscher, E. M., Arrivi, G., Ciocca, E., Filice, A., Golisano, B., Mazzilli, R., Prinzi, N., Colao, A., Faggiano, A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10040-x · Cited by 7
Lee, M., Jeong, K., Park, Y. R., & Rhee, Y. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155311 · Cited by 7
Immune checkpoint inhibitors-induced diabetes mellitus (review)
Chen, J., Hou, X., Yang, Y., Wang, C., Zhou, J., Miao, J., Gong, F., Ge, F., & Chen, W. (2024) · Endocrine · doi:10.1007/s12020-024-03942-w · Cited by 7
DISTERHAFT, P., Kerr, C., Barnett, D., & Salloum, M. (2024) · Cancer Reports · doi:10.1002/cnr2.70058 · Cited by 7
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2025
Landgraf, R., Heinemann, L., Schwarz, T., Niederau, C. M., Pleus, S., Tytko, A., Werner, C., Müller‐Wieland, D., Müller, U. A., Freckmann, G., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2566-7533 · Cited by 6
Go, S.-H., Cho, Y. K., & Koh, E. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0455 · Cited by 6
Liu, W., Li, C., Fang, Y., Cai, X., Zhu, Y., Ren, Q., Zhang, R., Zhang, M., Gao, Y., Han, X., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89668-9 · Cited by 6
Popovic, D. S., Koufakis, T., Kovačević, B., Rizzo, M., & Παπάνας, Ν. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2134343 · Cited by 5
Derr, A. G., Arowosegbe, A., Satish, B., Redick, S. D., Qaisar, N., Guo, Z., Vanderleeden, E., Trombly, M. I., Baer, C. E., Harlan, D. M., et al. (2022) · Diabetes · doi:10.2337/db22-0521 · Cited by 5
Kahkoska, A. R., Neumiller, J. J., Alexopoulos, A., Christiaens, A., Cukierman‐Yaffe, T., Ehrhardt, N. M., Huang, E. S., Idrees, T., Laffel, L. M., Lee, S. J., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-10053-3 · Cited by 5
Regenerative medicine approaches for treating diabetes: Current advances and future directions
Medenica, S., Abazović, D., Vuković, J., Vojinović, T., Tomović, F., Defeudis, G., Mazzilli, R., Kovačević, Z., Djurdjic, D., Prelević, V., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109232 · Cited by 5
Cardiometabolic perturbations arising from treatment with novel anticancer therapies
Bennetts, J. D., Sverdlov, A. L., & Ngo, D. T. M. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.10.008 · Cited by 5
Angelousi, A. G., Ziogas, D. C., Siampanopoulou, V., Mytareli, C., Anastasopoulou, A. N., Lyrarakis, G., & Gogas, H. J. (2024) · Diseases · doi:10.3390/diseases12020040 · Cited by 4
Wang, G., Wang, J., Dong, S., Zhang, Z., Zhang, W., & Zhao, J. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12486 · Cited by 4
Yan, J., Xie, Z.-Z., Morán, T., Gridelli, C., Zheng, M.-D., & Dai, S.-J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5211 · Cited by 4
Immune checkpoint inhibitors and endocrinopathies in pediatric brain tumor patients
Westermann, C. R., Davidson, T. B., Waters, K., Margol, A., & Cheung, C. C. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0243 · Cited by 3
Lin, M., Ye, R., Jhou, H., Chen, H., Kao, L., Hsieh, T. Y. J., Chen, Y., Sun, A. Y.-E., Zhang, X., Dai, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01940-0 · Cited by 3
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2024
Schwarz, T., Niederau, C. M., Pleus, S., Tytko, A., Landgraf, R., Werner, C., Müller‐Wieland, D., Müller, U. A., Freckmann, G., Schleicher, E. D., et al. (2025) · Die Diabetologie · doi:10.1007/s11428-024-01269-8 · Cited by 3
SARS-CoV-2-Vaccine-Related Endocrine Disorders: An Updated Narrative Review
Ishay, A., Oleinikov, K., & Shacham, E. C. (2024) · Vaccines · doi:10.3390/vaccines12070750 · Cited by 3
Gao, Y., Lin, M., & Deng, J. (2025) · Medicine · doi:10.1097/md.0000000000045414 · Cited by 3
A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report
Miyabayashi, M., Onishi, S., Yoshida, T., & Takemoto, M. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03755-x · Cited by 3
Karunakaran, U., Ha, E. Y., Elumalai, S., Won, K. C., & Moon, J. S. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14230 · Cited by 3
Sugai, K., Miwa, T., Kojima, J., Ueda, Y., Tsukahara, K., Nishi, H., & Suzuki, R. (2024) · Endocrine · doi:10.1007/s12020-024-03780-w · Cited by 3
Diddhenipothage, S. A. D. M., Warden, J., Herbert, K., Pofi, R., Joseph, R. N., Coupe, N. A., Payne, M., Tomlinson, J., & Turner, H. E. (2026) · Clinical Endocrinology · doi:10.1111/cen.70137 · Cited by 2
Management of Immunotherapy-Induced Type 1 Diabetes
Brady, V. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.07.002 · Cited by 2
Ardakani, K. Y., Passarella, G., Lania, A. G., Clementi, T. D., Fanti, A., Pepe, F. F., Capici, S., & Cazzaniga, M. E. (2026) · Current Oncology · doi:10.3390/curroncol33010028 · Cited by 2
Circulating T Cell Subsets in Type 1 Diabetes
Ferreira‐Hermosillo, A., Santana-Sánchez, P., Vaquero-García, R., García-Sáenz, M. R., Castro‐Ríos, A., Chávez-Rueda, A. K., Gómez-Díaz, R. A., Chávez-Sanchéz, L., & Legorreta-Haquet, M. V. (2025) · Cells · doi:10.3390/cells14010048 · Cited by 2
Kudo, S., Yokoo, K., Tanaka, N., Yamada, G., & Kitamura, Y. (2024) · Cureus · doi:10.7759/cureus.56302 · Cited by 2
Nakatake, N., Matsuda, M., & Kontani, H. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luae252 · Cited by 2
Li, Z., Han, K., Li, L., Han, X., Zhang, F., & Guo, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1642893 · Cited by 1
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2025
Landgraf, R., Heinemann, L., Schwarz, T., Niederau, C. M., Pleus, S., Tytko, A., Werner, C., Müller‐Wieland, D., Müller, U. A., Freckmann, G., et al. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01423-4 · Cited by 1
Landgraf, R., Heinemann, L., Schwarz, T., Niederau, C., Pleus, S., Tytko, A., Werner, C., Müller‐Wieland, D., Müller, U. A., Freckmann, G., et al. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3155 · Cited by 1
Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2023
Pleus, S., Tytko, A., Landgraf, R., Heinemann, L., Werner, C., Müller‐Wieland, D., Ziegler, A., Müller, U. A., Freckmann, G., Kleinwechter, H. J., et al. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01127-z · Cited by 1
Pătru, R. I., Ghigeanu, M., Barbu, M.-A., Ionescu, A.-I., & Antone-Iordache, I.-L. (2025) · Reports — Medical Cases Images and Videos · doi:10.3390/reports8010031 · Cited by 1
Immune checkpoint inhibitors and metabolic events: results from a European safety analysis
Longo, M., Mascolo, A., di Mauro, G., Gargiulo, S., Sportiello, L., Carbone, C., Bellastella, G., Maiorino, M. I., Capuano, A., & Esposito, K. (2025) · HORMONES · doi:10.1007/s42000-025-00726-3 · Cited by 1
Combined immune checkpoint inhibitor–induced type 1 diabetes: a rare but serious endocrinopathy
Emami, K., Goyal, S., AKULA, V., & Amoakohene, P. N. A. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag041 · Cited by 1
Diabetes mellitus geïnduceerd door immuuntherapie: een casus
Dekock, T., Taelman, T., Vanhaverbeke, G., Derijcke, S., & Ghysen, K. (2024) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.132 · Cited by 1
Inflammation and Diabetes Mellitus
Lim, S., Sarkar, S., & Ahima, R. S. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-39721-9_3 · Cited by 1
Crowder, V., & Brady, V. (2025) · Life · doi:10.3390/life15071063 · Cited by 1
Li, Y., Qu, K., Yang, Q., 张金铭, Xu, Y., Wang, H., Zhang, K., Wang, C., Abdul-Aziz, M. H., & Xie, J. (2026) · Diabetic Medicine · doi:10.1111/dme.70316 · Cited by 1
Matsumoto, N., IWASAKI, H. O., Sasai, Y., Aono-Soma, N., & Sekiya, M. (2025) · Cureus · doi:10.7759/cureus.91593 · Cited by 1
Ruiz-Esteves, K. N., SHANK, K. R., Colling, C., Ouyang, T., Zubiri, L., Villani, A., Reynolds, K. L., Sise, M. E., & Rengarajan, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1252 · Cited by 1
Jiang, Y., Cui, Y., Su, D., Yang, H., Chen, X., Qian, X., Tang, L., & Xu, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819809 · Cited by 1
Self-citationPatel, R. T., Kolkey, Z. L., Jung, J., Elghawy, O., Mullapudi, A., Xu, J. A., & Kaur, V. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251348662 · Cited by 1
Landgraf, R., Heinemann, L., Schwarz, T., Niederau, C. M., Pleus, S., Tytko, A., Werner, C., Müller‐Wieland, D., Müller, U. A., Freckmann, G., et al. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2874-4147 · Cited by 1
Research Advances of Immune Checkpoint Inhibitors Related Endocrine Adverse Events
王, 晶. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142381
Zhou, L., Liu, X., Xiao, N., Bai, G., & Li, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9051493/v1
Hyperglycemia during ICI Therapy: etiology, risk factors, and survival outcome
Shen, M., Wang, X., Gao, T., Yin, J., Bian, W., Zheng, X., Yang, T., & Shi, Y. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03018-8
Drug-induced glucose metabolism disorders: A disproportionality analysis based on the FAERS databasePreprint
Zhang, Z., Li, Q., Huang, T., Yang, X., Du, X., Deng, X., Wang, S., & Zhou, J. (2025) · medRxiv · doi:10.1101/2025.08.26.25334521
PD-1/PD-L1 pathway and the U-Curve paradigm: implications for type 1 diabetes immunotherapy
Chen, J., Zhang, H., Yu, P., Fu, L., & Yang, P. (2026) · European journal of medical research · doi:10.1186/s40001-026-04455-0
Miscellaneous Topics in Disorders of Endocrine Glands
Quarde, A. (2023) · Wiley eBooks · doi:10.1002/9781119863564.ch8
Galectin‐9 Modulates Autoimmunity: Roles in Tissue Inflammation and Organ Involvement
Liu, F., Zhou, X., Luo, J., Wang, Z., & Tao, Q. (2026) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.70010
Chronic and emerging immune-related adverse events from immune checkpoint inhibitors
Frey, C. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100011 · Cited by 1
Misra, P. S. (2024) · TSpace (University of Toronto)
Diabetic ketoacidosis in a patient with renal cell carcinoma on immune checkpoint inhibitor
Malkat, S., Tseke, D., Younes, Y. R., & Emmanuel, J. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-268141
Sarkar, A., Dhar, S., Bera, S., Chakravarti, M., Verma, A., Khan, M. A., Prasad, P., Das, J., Choudhury, P. R., Sultana, J., et al. (2026) · The Journal of Immunology · doi:10.1101/2024.04.04.588206
Duvall, L. E., Wainwright, L., Bryant, L., Sandy, G., Owusu-Yeboah, V., & Hurlstone, A. F. L. (2026) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632261475616
Parsapour, M., Sharif, P. M., & Rezaei, N. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156736
Worsening Hyperglycemia During Immune Checkpoint Inhibitor Therapy
Lee, I. J.-A., Takigawa, K., & Best, C. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_8
Wei, H.-H., Lai, Y.-C., Lin, G., Lin, C.-W., Chang, Y.-C., Chang, J. W., Liou, M.-J., & Chen, I.-W. (2024) · Figshare · doi:10.6084/m9.figshare.25045585
Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations
Herold, K. C., & Perdigoto, A. L. (2026) · Journal of Clinical Investigation · doi:10.1172/jci202477
Alharbi, T. H., Alzahrani, H. A., Alromaihi, R. A., alzahrani, S., Alromaihi, M., & Kamrul-Hasan, A. B. M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113439
Diabete mellito indotto da inibitori dei checkpoint immunitari: un approccio tecnologico
Carrieri, F., Coluzzi, S., Mascitti, M., & Dalmazi, G. D. (2025) · il Diabete · doi:10.30682/ildia2502e
Terapia con inibitori del checkpoint immunitario e rischio di diabete di tipo 1
Latino, A., & Buzzetti, R. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01338-y
Vega Sáez, G., Murgadas López, C., Corvalán Gutiérrez, R., Zaninovic Abogabir, I., & Pradenas Neumann, B. (2025) · Revista Andes · doi:10.5281/zenodo.15634906
Mao, H., Jiang, X., Huang, X., Fang, J., Mao, Y., & Hong, L. (2026) · PubMed Central · doi:10.1097/md.0000000000051420
Metadata
- Authors
- Chen, X., Affinati, A. H., Lee, Y., Turcu, A. F., Henry, N. L., Schiopu, E., Qin, A., Othus, M., Clauw, D., Ramnath, N., & Zhao, L.
- Affiliations
- University of Michigan (US)
- Biostatistics and Biomathematics Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Ann Arbor, MI
- Department of Anesthesiology, University of Michigan, Ann Arbor, MI
- Corresponding author
- Zhao, Lili
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-03-03
- Volume
- 45
- Issue
- 5
- Pages
- 1170-1176
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9174959
- OpenAlex
- W4214883428
- Cited by
- 93
- References
- 33
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 26 · 2023: 17 · 2022: 6
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA046592)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020572)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, type 1 diabetes, immune-related adverse events, CTLA-4, PD-1, PD-L1, pregestational diabetes, immunosuppressants, risk factors, survival, cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Diabetes Mellitus, Type 1, Humans, Retrospective Studies, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.